Trial Profile
Phase II Study to Evaluate the Role of Bortezomib in the Management of Relapsed Acute Promyelocytic Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Arsenic trioxide
- Indications Acute promyelocytic leukaemia
- Focus Adverse reactions
- Acronyms PIAPL
- 01 Oct 2013 New trial record